Gong et al. demonstrated that elevated levels of TFEB alleviated the development of NAFLD, possibly through the upregulation of fibroblast growth factor 21 (FGF21) expression by targeting the promoter of FGF21 [142]. The gene discussed is TFEB; the disease is metabolic dysfunction-associated steatotic liver disease.